Why use a Premade Library for well-known immune checkpoints like PD-1 or TIGIT?

While many checkpoints are well-studied, there is a constant demand for Next-Generation Antibodies with: Unique Epitopes: Targeting non-canonical domains to overcome resistance to existing therapies. Optimized Affinity: Fine-tuning affinity to balance efficacy and toxicity (avoiding "on-target, off-tumor" effects). Speed: Our Premade Phage & Yeast Display Libraries (10^11 diversity) allow you to identify novel, patentable lead candidates in weeks, significantly faster than traditional hybridoma methods.

Can you discover antibodies that distinguish between highly homologous checkpoint family members?

Yes. Immune checkpoints often belong to large families (e.g., the B7 family or CD28 family) with high structural similarity. We utilize a Competitive Panning Strategy, using homologous non-target proteins as "decoy" antigens to deplete non-specific binders. This ensures our antibodies exhibit high selectivity for the specific checkpoint of interest (e.g., targeting OX40 without binding OX40L).

Do you provide functional validation for ligand-receptor blocking?

Absolutely. Beyond simple binding assays, we offer integrated Blocking Characterization: Competitive ELISA/FACS: Demonstrating the antibody's ability to interrupt the interaction between the checkpoint and its natural ligand (e.g., PD-1/PD-L1).

How do you handle complex "Checkpoint Receptors" that require native conformation?

For multi-pass transmembrane checkpoints or receptors that require specific glycosylation patterns, we utilize Yeast Display integrated with Whole-Cell Panning. This allows the library to interact with the checkpoint in its native, membrane-bound state on human cell lines, ensuring the discovered antibodies are biologically relevant and functionally active.

Can the antibodies be engineered into Bi-specific or Multi-specific formats?

Yes. Our discovery platform provides sequences in modular formats (scFv or Fab). These are ideal building blocks for: Dual Checkpoint Blockade: Target-specific scFvs for bivalent formats (e.g., PD-1/CTLA-4 bispecifics). Fc-Engineering: Modifying the Fc region to either enhance ADCC for depleting regulatory T cells (Tregs) or eliminate effector functions for pure antagonistic blocking.

Immune Checkpoint Therapy Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Creative Biolabs accelerates your immuno-oncology program by bypassing immunization. We leverage massive premade human antibody libraries and specialized ligand-competition screening strategies to identify functional candidates that modulate immune responses, ranging from high-potency antagonists to precision agonists.

Speak with an Expert. Get Pricing.

Antibody Discovery for Immune Checkpoint

Targeting immune checkpoints requires more than just binding; it requires demonstrable biological function. Whether your goal is disrupting a high-affinity ligand interaction, such as the PD-1/PD-L1 axis, or clustering receptors for agonistic activation, including OX40 and 4-1BB, standard screening often yields sticky binders that fail in functional assays.

Creative Biolabs addresses this challenge by combining our massive premade human libraries with specialized ligand-guided screening. We navigate this vast diversity to isolate developable, high-affinity antibodies that effectively break immune tolerance or enhance effector function. This approach delivers downstream-ready leads with greater speed and reliability than traditional immunization.

Functional Precision
Direct screening for ligand-receptor blockade or receptor activation.

Cross-Species Reactivity
Strategies to identify binders cross-reactive to Cynomolgus or Mouse (Surrogates).

Diverse Epitope Coverage
Access rare epitopes on complex targets (e.g., TIM-3, LAG-3, TIGIT).

Developability-First
Human frameworks optimized for stability and low immunogenicity.

Accelerated Timelines
Move to in vivo syngeneic models and combinatorial studies in weeks.

Request a Feasibility Assessment

How We Work

Inputs

Target name (e.g., TIGIT), MoA (Antagonist/Agonist), Cross-reactivity needs (Cyno/Mouse), Ligand info.

Workflow

Fig.1 Antigen Design. (Creative Biolabs AI)

Antigen Design

Fig.2 Enrichment (Panning). (Creative Biolabs AI)

Enrichment (Panning)

Fig.3 Clone Screening. (Creative Biolabs AI)

Clone Screening

Fig.4 Functional Selection. (Creative Biolabs AI)

Functional Selection

Fig.5 Sequence Analytics. (Creative Biolabs AI)

Sequence Analytics

Fig.6 IgG Conversion. (Creative Biolabs AI)

IgG Conversion

Deliverables

Ranked functional binders, epitope bins, sequence families, IgG mini-panel, full report.

Discuss Your Screening Strategy with an Expert

Ready-to-Screen Antibody Libraries

We offer a curated selection of libraries optimized for finding rare functional epitopes on checkpoint targets.

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 ☆Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Find the Perfect Library for Your Target

Case Study: High-Diversity Libraries, High-Impact Outcomes

Discovery of Potent Blocking Antibodies for Next-Generation Immune Checkpoints
Objective	The success of cancer immunotherapy relies heavily on the ability to identify antibodies that do more than just bind; they must functionally block the interaction between immune checkpoint receptors (e.g., PD-1, TIGIT, or LAG-3) and their respective ligands. This case study highlights our capability to utilize our Premade Camel Synthetic Single Domain Antibody Library to rapidly isolate V_HH clones with high blocking efficiency, using a ligand-mediated competitive elution strategy.
Targeted Functional Screening	To ensure the discovery of antibodies with biological activity, we implemented a specialized In-solution Functional Selection workflow designed to favor clones that compete for the same binding site as the natural ligand. Materials: Target 1 (Immune Checkpoint Receptor), Ligand 1 (Natural Binding Partner) Library: Our Premade Synthetic Camelid V_HH Library, optimized for high diversity and structural stability. Precision Screening Workflow: Pre-counter Selection: Remove matrix-binding background. Ligand-Competitive Elution: By adding an excess of Ligand 1, we specifically "competed off" and recovered only those V_HH clones that bind to the functional interface (the ligand-binding pocket).
Key Results	1. Efficient Library Enrichment The screening process yielded the increase in phage titers across successive rounds. The use of Ligand 1 for elution ensured that the enriched pool was highly focused on functional candidates rather than non-blocking binders. 2. Validation of Blocking Activity Following monoclonal identification, over 5 unique binders were initially identified. These were further subjected to a Competitive Blocking ELISA. Three lead candidates demonstrated superior blocking activity, successfully preventing the interaction between Target 1 and Ligand 1 in a dose-dependent manner.

Request a Fixed‑Price Quote

Related Services

Fig.9 Antibody Discovery for Immunotherapy. (Creative Biolabs Authorized)

Premade Antibody Library based Antibody Discovery Service for CAR-T Therapy

Premade Antibody Library based Antibody Discovery Service for ADC Therapy

Why Choose Us?

Mechanism-Driven Screening

We don't just find binders; we isolate functional modulators. By integrating ligand-competition panning early in the process, we identify blockers that effectively disrupt inhibitory signaling pathways from the outset.

Massive Diversity

Our premade human antibody libraries provide the vast sequence space necessary to identify rare clones against challenging or conserved checkpoint targets.

The V_HH Advantage

Our specialized V_HH library yields high-affinity single-domain antibodies. These robust scaffolds offer exceptional stability and deep tissue penetration, which is a critical factor for penetrating the dense microenvironments of solid tumors.

Cross-Species Reactivity

We proactively screen for human, cyno, and mouse cross-reactivity. This strategy enables you to enter syngeneic mouse models and toxicology studies using a single lead candidate, eliminating the need for separate surrogate development.

Radical Data Access

You receive end-to-end data, including NGS clonotype clustering and full sequence deliverables. This transparency empowers your team to make informed, data-driven decisions for IP expansion.

Full-Spectrum Support

From high-purity protein biotinylation and MHC assembly to sophisticated functional characterization, we provide a seamless end-to-end solution for your checkpoint discovery programs.

Get a Milestone‑Based Quote

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

Why use a Premade Library for well-known immune checkpoints like PD-1 or TIGIT?
While many checkpoints are well-studied, there is a constant demand for Next-Generation Antibodies with: Unique Epitopes: Targeting non-canonical domains to overcome resistance to existing therapies. Optimized Affinity: Fine-tuning affinity to balance efficacy and toxicity (avoiding "on-target, off-tumor" effects). Speed: Our Premade Phage & Yeast Display Libraries (10¹¹ diversity) allow you to identify novel, patentable lead candidates in weeks, significantly faster than traditional hybridoma methods.
Can you discover antibodies that distinguish between highly homologous checkpoint family members?
Yes. Immune checkpoints often belong to large families (e.g., the B7 family or CD28 family) with high structural similarity. We utilize a Competitive Panning Strategy, using homologous non-target proteins as "decoy" antigens to deplete non-specific binders. This ensures our antibodies exhibit high selectivity for the specific checkpoint of interest (e.g., targeting OX40 without binding OX40L).
Do you provide functional validation for ligand-receptor blocking?
Absolutely. Beyond simple binding assays, we offer integrated Blocking Characterization: Competitive ELISA/FACS: Demonstrating the antibody's ability to interrupt the interaction between the checkpoint and its natural ligand (e.g., PD-1/PD-L1).
How do you handle complex "Checkpoint Receptors" that require native conformation?
For multi-pass transmembrane checkpoints or receptors that require specific glycosylation patterns, we utilize Yeast Display integrated with Whole-Cell Panning. This allows the library to interact with the checkpoint in its native, membrane-bound state on human cell lines, ensuring the discovered antibodies are biologically relevant and functionally active.
Can the antibodies be engineered into Bi-specific or Multi-specific formats?
Yes. Our discovery platform provides sequences in modular formats (scFv or Fab). These are ideal building blocks for: Dual Checkpoint Blockade: Target-specific scFvs for bivalent formats (e.g., PD-1/CTLA-4 bispecifics). Fc-Engineering: Modifying the Fc region to either enhance ADCC for depleting regulatory T cells (Tregs) or eliminate effector functions for pure antagonistic blocking.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: